News about "Swedish Orphan Biovitrum AB"

Sobi Completes Acquisition of Arthrosi Therapeutics to Strengthen Gout Pipeline with Phase III Asset Pozdeutinurad

Sobi Completes Acquisition of Arthrosi Therapeutics to Strengthen Gout Pipeline with Phase III Asset Pozdeutinurad

Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.

Swedish Orphan Biovitrum AB | 11/02/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members